Zyomyx Raises $10M
Online staff -- Electronic News, 2/12/2004
Biochip maker Zyomyx, a late stage company, has won $10 million in venture funding in a round led by CSFB Private Equity and including many existing investors.
The Hayward, Calif.-based company develops silicon-based biochips for protein analysis.
"We are extremely gratified by the strong interest from investors in this late stage round of financing," said Bob Monaghan, president and CEO, in a statement. "This investment provides for line expansion of our novel biochip platform, which we introduced with the Human Cytokine Biochip in 2003."
The company's customers include top pharmaceutical, biotech and academic institutions, Zyomyx said.
The company expects to launch its new Murine Cytokine Biochip in April, and some additional biochips later this year.
Also participating in the round of funding were existing investors Alloy Ventures, Lilly BioVentures, Hambrecht & Quist Capital Management, Mediphase Venture Partners and BioOne Capital Pte Ltd., the dedicated biomedical services investment arm of the Singapore Economic Development Board. |
